SUMMARY
INTRODUCTION
Palmar-plantar erythrodysesthesia (PPE) or hand-foot syndrome is a relatively frequent dermatologic toxic reaction that is associated with a number of chemotherapeutic drugs (1) . This syndrome was first described by Lokich and Moore in 1984 on a patient receiving continuous infusion of 5-FU (2) . Peglated liposomal doxorubicin (PLD) is an extended-release formula of conventional doxorubicin and when the PLD is used with the current proven dose as 50 mg/m 2 in every 4 weeks PPE is seen in 50% of patients and 20% of these cases appear to be grade 3 PPE (3, 4) .
Ensuring the safety of PLD, which is an important agent in the advanced ovarian cancer use, would improve the quality of life of patients with ovarian cancer. Afterwards, the patient was followed with tamoxifen.
The patient was followed approximately 1 year and increase of CA125: 256 U / ml and detection of more than one lymph nodes in pelvic CT scan was evaluated as recurrence, and the patient received 6 cycles of paclitaxel-carboplatin 6 AUC chemotherapy. After 
DISCUSSION
Palmar-plantar erythrodysesthesia (PPE) or hand-foot syndrome is a relatively frequent dermatologic toxic reaction that is associated with a number of chemotherapeutic drugs (1) . PPE usually appears 2-12 days after initiation of chemotherapy as dysesthesia and tingling, and after 3-4 days these symptoms progress to symmetrical edema and erythema in palms, soles. Vacuolised areas in the basal layer, perivascular lymphocytic infiltration in the dermis and deposits of melanin are contained. Dermal changes include dilated blood vessels, papillary edema and superficial perivascular lymphohistiocytic infiltration (1) .
PLD is an extended release formulation of doxorubicin hydrochlorid buried within the peglated liposome. This formula is being used for metastatic breast cancer patients with increased cardiac risk, advanced ovarian cancer patients for whom platinum-based chemotherapy had failed (as in our case), and for immune deficiency syndromes associated with Kaposi's sarcoma.
Embedding of doxorubicin into liposomes causes a change in pharmacokinetic and biodistrubition of the drug, and as a result toxic effects caused by doxorubicin in particular cardiac toxicity is reduced (3) (4) (5) . The incidence of PPE in patients receiving PLD is higher compared to patients receiving conventional doxorubicin (3) (4) (5) . Studies have shown that when the effective dose of PLD 50 mg/m 2 is used for 4 weeks, PPE was observed in 50% of the patients and 20% of these cases were grade 3 PPE (3) (4) .
Pathophysiology of the drugs causing PPE is poorly understood. PLD might cause extravasation from the microcapillary following local trauma caused by routine activity. Increased concentration of PLD have been identified in the eccrine sweat glands of hands and feet. Coverage of hydrophilic liposomes in these areas might facilitate the accumulation and occurrence of the syndrome in hands and feet might be explained by high amounts of eccrine glands in these regions (6) .
In a study, doxorubicin was observed in the sweat of extrator channels of eccrine sweat glands in 10 patients received PLD for various malignancies (6) . In the same study, only 5 patients with hyperhidrosis in the hands and feet developed PPE (6) . Regional temperature gradient in the lower extremities, rapid cell proliferation, gravitational force and the vascular anatomy contribute to the development of typical localization of this syndrome in the palms and soles of the feet (7, 8) . In another study, contribution of local pressure and skin trauma was examined (9) . In a study, Lyass Prevention strategies of PPE include various pharmacological and non-pharmacological treatments such as avoiding excessive pressure or rubbing the skin and avoiding situations that cause dilation of blood vessels (such as hot showers or sun exposure) (10) . In a retrospective study, in 17 women application of regional cold to hands and ankles and consumption of cold drinks during PLD infusion reduced the severity and incidence of PPE compared to 3 women that did not receive the same treatment (11) . The effect of cold application occurs as a result of reduction of drug circulation in the lower extremities due to vasoconstriction. This causes reduced drug extravasation and tissue toxicity in the surrounding tissue. At the same time, low temperature leads to a decrease in the concentration of uncapsulated doxorubicin by stabilizing the liposomal configuration (11) .
One of the investigated agents for prophylaxis of PPE is pyridoxine, because in rodents with pyridoxal phosphate deficiency acrodini, a PPE-like situation, was observed (12) , and in an uncontrolled study it has been shown that pyridoxine might reduce the incidence and severity of PPE develops due to 5-FU infusion (13) . Many researchers evaluated dexamethasone in the prophylaxis of PPE. In a prospective study evaluating the dexamethasone premedication (14) 23 patients received PLD 50 mg/m2 every 28 days without dexamethasone because of recurrent gynecologic malignancies. 9 patients developed grade 2-4 PPE and PPE treatment was stopped unt›l PPE disappeared and then started again. Once the treatment was started again 6 out of nine patients received 8 mg dexamethasone twice a day 5 days before the start of infusion and the given dose was discontinued by reducing in the next 2 days. All of the 6 patients received dexamethasone did not need to delay or reduce the dose of the therapy for an average of 7 cycles of chemotherapy, but patients that did not reveived dexamethasone needed dose reduction or delay of the therapy.
Another agent investigated for the prophylaxis of PPE is amiphostine. Lyass and colleagues (15) reported that Since dimethyl sülfokside (DMSO) a topical pharmacological agent has properties as a potent free radical scavenging it has been were investigated for potential benefit in PPE. Following the topical application DMSO rapidly penetrates the tissues and could be successfully used in the treatment of conventional doxorubicin extravasation (16) .
The properties of administration and pharmacokinetics of PLD seem to influence the severity and incidence of PPE. Clinical data showed that after multiple injections of PPE the development of PLD increases (9) . In their studies, Lyass and colleagues (9) , and Ranson and colleagues (7) investigated the effect of different doses and tariffs on PPE incidence in patients with breast cancer. These studies showed that applications in the short term (meaning short-term of dose ranges) are associated with more toxicity. This effect seems to be independent of the dose intensity. When the dose and pharmacokinetic parameters of PLD are analyzed stomatitis and decreasein leukocyte count were found strongly correlated with dose and Cmax, while the severity of PPE was correlated only with the half-life (t1/2) (18) . Previous preclinical data indicate that there there is a relationship between severity of PPE and dose intensity (19) . On the other hand, the impact of changing the dose intensity on clinical outcomes is not clear. Rose et al. (20) . partial response in the patients group receiving 50 mg/m 2 . In a prospective study (21) , when 40 mg/m 2 of dose was applied to 49 patients with platinum and paclitaxel resistance ovarian cancer (phase 2 study), 4 out of 44 patients (9%) showed an objective response.
The rate of PPE in any grade was 18%. Grade 
